Fenofibrate-induced liver injury.

TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequently observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological because fenofibrate activates the gene expression of the aminotransferases. Recently, fenofibrate has been used not only for hypercholesterolemia but also for primary biliary cirrhosis (PBC)[1,2]. However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug.

• Publication year

  2005

• Venue

  World Journal of Gastroenterology

• Publication date

  2005-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3748/WJG.V11.I48.7702PMID 16437706PMCID PMC4727212
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

  2004cited by this paper
• Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers.

  2002cited by this paper
• Is bezafibrate histologically effective for primary biliary cirrhosis?

  2002cited by this paper
• Fenofibrate treatment in patients with primary biliary cirrhosis

  2002cited by this paper
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  2001cited by this paper
• Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

  2000cited by this paper
• Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study

  2000cited by this paper
• A novel treatment for refractory primary biliary cirrhosis?

  2000cited by this paper
• Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.

  1998cited by this paper

• PPARα: A potential therapeutic target of cholestasis

  2022cites this paper
• Biopsy-confirmed fenofibrate-induced severe jaundice: A case report

  2021cites this paper
• Fenofibrate‐induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database

  2019cites this paper
• Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver

  2018cites this paper
• Effect of fenofibrate on uric acid level in patients with gout

  2018cites this paper
• Identification and Characterization of Fenofibrate-Induced Liver Injury

  2017cites this paper
• Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

  2016cites this paper
• Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

  2015cites this paper
• Effects of Fenofibrate on Adiponectin Expression in Retinas of Streptozotocin-Induced Diabetic Rats

  2014cites this paper
• Peroxisome Proliferator Activator Receptor (PPAR)-γ Ligand, but Not PPAR-α, Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver

  2014cites this paper
• Hepatotoxicity of Cardiovascular and Antidiabetic Drugs

  2013cites this paper
• Effects of a crude Aloe vera leaf extract on diet-induced metabolic dysfunction in growing rats

  2012cites this paper
• Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

  2011cites this paper
• Pathogenesis of alcoholic liver disease: the role of nuclear receptors

  2010cites this paper
• Novel action of 7‐O‐galloyl‐d‐sedoheptulose isolated from Corni Fructus as a hypertriglyceridaemic agent

  2009cites this paper
• Acute cholestatic hepatitis induced by fenofibrate

  2009cites this paper
• Mechanisms of Resistance of Hepatocyte Retinoid X Receptor α-Null Mice to WY-14,643-induced Hepatocyte Proliferation and Cholestasis*

  2009cites this paper
• Fibrate-associated adverse effects beyond muscle and liver toxicity.

  2008cites this paper
• Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.

  2007cites this paper
• World Journal of Diabetes

  year unknowncites this paper